

AstraZeneca partners with Alveofit lung diseases management in India

19 August 2022 | News

Aims to embed latest technological advancements in diagnosing and managing lung disorders and associated non-communicable diseases like asthma, pulmonary fibrosis and COPD



[AstraZeneca](#) India has announced its partnership with Alveofit, a SaaS-IoT enabled respiratory healthcare platform, to offer IoT enabled handheld spirometers at hospitals across the country.

As a part of this partnership with Alveofit, AstraZeneca will provide Alveofit IoT enabled handheld spirometers to the clinics and last mile hospitals to enable point of care spirometry for optimized management of different lung associated non-communicable diseases. This will help track patients remotely and even conduct telespirometry with comprehensive care management solutions.

AstraZeneca has deployed spirometers at selected hospitals across the country. This include ESIC hospitals for industrial employees, Command and Military Hospitals, General Hospitals and last mile clinics in cities like Lucknow, Chennai, Nagpur, Delhi, Ahmedabad and Kolkata. In a pilot project conducted before starting this initiative, 2800+ patients were tested and around 35-40% were diagnosed with lung issues across all the age groups right from 10-12 year old to 85-90 year old through this deployment.

This deployment was the need of the hour given the rising pollution and post COVID-19 world aiding the diagnosis of the respiratory diseases early in the cycle, so as to stop them from progressing ahead and help raise the standard of lives of the patients leading them to live a symptom-free life."

As a next step, AstraZeneca and Alveofit are planning to expand this initiative to tier-2 and tier-3 towns across India to make basic respiratory diagnosis and care accessible for everyone.